Korean Circ J.  2023 Sep;53(9):619-620. 10.4070/kcj.2023.0161.

Should We Use Renin-AngiotensinAldosterone System Inhibitors Routinely in Patients With Hypertrophic Cardiomyopathy?

• Park JH

• KMID: 2545955
• DOI: http://doi.org/10.4070/kcj.2023.0161

Reference

1. Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 79:390–414. PMID: 35086661.

2. Lee HJ, Kim J, Chang SA, Kim YJ, Kim HK, Lee SC. Major clinical issues in hypertrophic cardiomyopathy. Korean Circ J. 2022; 52:563–575. PMID: 35929051.

3. Park CS, Rhee TM, Lee HJ, et al. Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients. Korean Circ J. 2023; 53:606–618. PMID: 37653696.

4. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J. 2023; 53:217–238. PMID: 37161681.

5. Zhang Y, Liu MH, Zhang M, et al. Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth. J Geriatr Cardiol. 2023; 20:109–120. PMID: 36910243.

6. Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021; 27:1818–1824. PMID: 34556856.

7. Kim KH, Pereira NL. Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure. Korean Circ J. 2021; 51:797–836. PMID: 34327881.